Oxervate

Drug Overview

In the highly specialized field of Ophthalmology, the management of corneal health is fundamental to preserving clear vision. Oxervate represents a significant breakthrough in clinical care, as it is the first available medication in the Nerve Growth Factor drug class. This innovative therapy is specifically designed to address a rare and potentially blinding condition known as Neurotrophic Keratitis (NK). Unlike traditional lubricants or surgical interventions, Oxervate acts as a Targeted Therapy to restore the natural healing mechanisms of the ocular surface by addressing the underlying nerve damage that characterizes this disease.

Neurotrophic Keratitis occurs when the trigeminal nerve, which provides sensation and vital “trophic” (nutritional) support to the cornea, is damaged. This leads to a loss of corneal sensitivity, epithelial breakdown, and eventually, non-healing ulcers. Oxervate provides a sophisticated pharmacological solution to this neurological-driven ocular failure, offering hope to patients suffering from chronic ocular surface disease.

• Generic Name / Active Ingredient: Cenegermin-bkbj (Recombinant Human Nerve Growth Factor)
• US Brand Names: Oxervate
• Route of Administration: Topical Drops (Preservative-Free Ophthalmic Solution)
• FDA Approval Status: Fully FDA-approved for the treatment of Neurotrophic Keratitis.

What Is It and How Does It Work? (Mechanism of Action)

Oxervate is a recombinant human nerve growth factor (rhNGF). To understand its role as a Targeted Therapy, one must examine the molecular relationship between corneal nerves and corneal health. In a healthy eye, the cornea is one of the most densely innervated tissues in the human body. These nerves do not just provide sensation; they release essential proteins called “neurotrophins” that tell the corneal epithelial cells to grow, divide, and heal.

At the molecular and physiological level, cenegermin-bkbj acts as an exogenous source of these vital neurotrophins. When the medication is applied topically, the cenegermin protein binds to specific high-affinity receptors on the corneal surface, primarily the TrkA (tropomyosin receptor kinase A) and p75NTR (p75 neurotrophin receptor).

Binding to TrkA triggers an intracellular signaling cascade that promotes the survival, proliferation, and differentiation of corneal epithelial cells. Furthermore, it stimulates the production and release of endogenous growth factors. On a physiological level, this mechanism restores the trophic support that was lost due to nerve damage. It directly encourages the cornea to close persistent epithelial defects (PED) and heal corneal ulcers. Additionally, research suggests that rhNGF may support the survival of corneal nerves themselves, potentially improving corneal sensitivity over time and stabilizing the blood-retinal barrier indirectly by maintaining the structural integrity of the entire globe.

FDA-Approved Clinical Indications

Oxervate is meticulously indicated for the treatment of specific stages of corneal degeneration.

• Primary Indication: Treatment of Neurotrophic Keratitis (NK), including Stage 1 (persistent epithelial irregularities), Stage 2 (persistent epithelial defects), and Stage 3 (corneal ulcers) in both adult and pediatric patients.
• Other Approved & Off-Label Uses:
  • Post-Surgical Healing: Occasionally utilized off-label to support the ocular surface after extensive corneal surgeries or transplants in patients with poor healing capacity.
  • Chronic Dry Eye Disease (DED): Investigational use in severe cases where nerve damage is suspected to be a primary driver of the condition.

Primary Ophthalmology Indications for Visual Preservation:

• Preserving Visual Acuity: By promoting the complete closure of corneal ulcers, Oxervate prevents the formation of dense, central stromal scars that would otherwise lead to permanent blindness.
• Stabilizing the Ocular Surface: The medication restores the structural integrity of the cornea, preventing thinning (melting) and potential perforation of the globe.
• Restoring Ocular Homeostasis: By addressing the underlying “nerve-to-epithelium” communication failure, it provides a long-term solution rather than a temporary “bandage” for chronic surface disease.

Dosage and Administration Protocols

The administration of Oxervate is intensive and requires strict patient adherence to a specific 8-week treatment cycle. The medication is provided in a complex kit that must be kept refrigerated until use.

Specific Instructions:

• Preservative-Free Handling: Oxervate is Preservative-Free. Each single-use vial must be used immediately and discarded.
• Preparation: Each weekly carton contains a vial adapter and single-use pipettes. Patients must be trained on how to extract the solution without contaminating the vial.
• Wait Times: If using other topical medications, wait at least 15 minutes before or after applying Oxervate.
• Contact Lenses: Therapeutic bandage lenses may be used under a physician’s supervision, but standard cosmetic lenses should be avoided during the 8-week course.
• Punctal Occlusion: Gently press the inner corner of the eye for 1 minute to ensure maximum absorption by the cornea and minimize systemic exposure.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical data from 2020-2026 confirms that Oxervate is highly efficacious in treating the underlying causes of Neurotrophic Keratitis. In two pivotal multicenter, randomized, double-masked, vehicle-controlled clinical trials (REPARO and NGF0214), Oxervate demonstrated superior results in achieving complete corneal healing.

Precise numerical data from these trials indicated that between 70% and 72% of patients treated with Oxervate achieved “complete corneal healing” (defined as 0 mm of staining in the lesion area) within the 8-week treatment period. This was compared to only 29% to 33% in the control groups. Furthermore, the durability of this healing was impressive, with approximately 80% of healed patients remaining stable without recurrence six months after treatment. While it does not treat the posterior segment directly—and thus does not show a mean change in Central Retinal Thickness (CRT) on OCT—the preservation of Best Corrected Visual Acuity (BCVA) is significant. Patients who achieved complete healing avoided the 3 to 5 line loss in visual letters often seen in cases of progressive corneal melting.

Safety Profile and Side Effects

Black Box Warning: There is NO Black Box Warning for Oxervate.

Oxervate is generally well-tolerated, with most side effects remaining localized to the eye.

Common Side Effects (>10%):

• Eye Pain: The most frequent side effect (approximately 16%), often described as a stinging or aching sensation, which may ironically indicate the return of corneal sensation.
• Corneal Deposits.
• Foreign body sensation.
• Ocular hyperemia (redness).
• Increased lacrimation (tearing).

Serious Adverse Events:

• Corneal Neovascularization: The growth of blood vessels into the clear cornea.
• Infectious Keratitis: Risk of secondary infection due to the frequent administration and the underlying compromised state of the eye.
• Severe Eye Pain: In rare cases, pain may be severe enough to require temporary discontinuation.

Management Strategies: Sterile administration technique is mandatory to prevent secondary infection. Because this is a Targeted Therapy involving growth factors, physicians must monitor for “floaters” or sudden changes in vision to rule out any deep inflammatory response. Proper drop instillation training is vital to ensure the drug reaches the damaged tissue without contamination.

Research Areas

Direct Clinical Connections: Current research (2020-2026) is investigating Oxervate’s interaction with the health of the optic nerve head. There is emerging interest in whether Nerve Growth Factor can offer neuroprotection of the optic nerve fibers in severe glaucoma or degenerative retinal conditions. Additionally, studies are looking at the drug’s impact on goblet cell density, which is critical for long-term tear film stability.

Generalization: The field is exploring Novel Delivery Systems, such as sustained-release subconjunctival implants or bio-erodible ocular inserts. These aim to provide a constant level of rhNGF over 8 weeks, potentially replacing the current 6-times-daily dosing schedule. Furthermore, the development of Biosimilars for growth factors is a topic of active clinical trial investigation.

Severe Disease & Surgical Integration: Oxervate is being studied as a critical adjunct in preventing blindness in end-stage corneal disease. Research is evaluating its use before and after corneal transplants (keratoplasty) to ensure that the donor tissue receives the necessary “trophic” signals to survive and integrate into the host eye.

Disclaimer: These studies regarding Oxervate and its potential applications are currently in the preclinical or early clinical research phase and are not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A thorough exam including Baseline Visual Acuity, Tonometry (IOP measurement), and a Slit-lamp exam with fluorescein staining is mandatory.
• Ocular Imaging: Corneal photography and Optical Coherence Tomography (OCT) of the anterior segment are used to document the depth and area of the ulcer.
• Specialized Testing: Corneal sensitivity testing (Cochet-Bonnet esthesiometry) is essential to confirm the diagnosis of Neurotrophic Keratitis.
• Screening: Patients must be screened for active ocular infections, as Oxervate should not be started until any infection is controlled.

Monitoring and Precautions

• Vigilance: Patients should be monitored every 1 to 2 weeks during the 8-week course to track epithelial healing.
• Lifestyle: Use UV protection (sunglasses) for photophobia. Eyelid hygiene (lid scrubs) should be maintained to prevent secondary infection.
• Actionable Advice: Keep the medication kit in the refrigerator and follow the provided weekly log to ensure no doses are missed.

Do’s and Don’ts

• DO use all 6 doses every day; the effectiveness depends on consistent exposure.
• DO report any sudden, severe eye pain to your doctor immediately.
• DON’T touch the pipette tip to your eye or any surface.
• DON’T stop the medication early even if the eye “feels” better, as the 8-week course is necessary for stable healing.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice. Oxervate is a prescription medication that must be used under the direct supervision of an ophthalmologist or cornea specialist. FDA statuses and clinical protocols as of 2026 are subject to change based on ongoing regulatory and clinical findings. Always consult with a licensed healthcare professional for the diagnosis and treatment of any ocular condition. Standard clinical protocols should always be prioritized over general information.